Dose escalation schedule: difference between revisions
Diff·revision 18 → 19·08:35, 26 Jul 2025
Difference between revision 18 and revision 19 of Dose escalation schedule. 5 lines changed; the page grew by 586 bytes.
| Revision 18 — 01:38, 29 Jun 2025 NurseNoteNessa (talk) correct the unit conversion — U-100 not U-40 4,096 bytes +23 | Revision 19 — 08:35, 26 Jul 2025 ForgeryFinder (talk) add the note about drawing air before withdrawal 4,682 bytes +586 | ||
|---|---|---|---|
| 33 | These are the schedules used in the pivotal trials and reflected in product labelling.{{r|jastreboff2022}} The table is descriptive of published schedules; it is not guidance, and this wiki gives no dosing advice. | 33 | These are the schedules used in the pivotal trials and reflected in product labelling.{{r|jastreboff2022}} The table is descriptive of published schedules; it is not guidance, and this wiki gives no dosing advice. |
| 34 | 34 | ||
| + | 35 | == Deviations and their consequences == | |
| + | 36 | Two deviations are commonly discussed. Escalating faster than the schedule increases gastrointestinal events; the trials that established these schedules did so by finding the pace at which discontinuation was acceptable.{{r|wilding2021}} | |
| + | 37 | ||
| + | 38 | Escalating more slowly, or holding at an intermediate dose, is a recognised approach where tolerability is limiting, and product labelling for several agents permits it explicitly. The cost is that the maintenance dose — and therefore the effect size observed in trials at that dose — is not reached. | |
| + | 39 | ||
| 35 | == References == | 40 | == References == |
| 36 | {{reflist}} | 41 | {{reflist}} |